Build community with your colleagues in our new space for knowledge exchange and professional networking.
Connect
Build a knowledge base of industry best practices, sample documents and more in our resource library.
Learn
Ask questions of your peers to gain the tools you need to communicate with leaders and partners in your field.
Explore
I just wanted to give one follow-up if I could. In the BMJ publication the following quote appears. "…there was a noticeable association between increasing anticholinergic burden over the previous 4-20 years and incident dementia…These relations were ...
Thanks Pat. So what absolute difference in your composite cure definition between two therapies/procedures would lead you to consider one therapy superior to the other (eg 5%, 10%, 15%)? Nick Abraham (Nick) Morse MD,MBA Chief of Urogynecology, Director ...
Thanks for your thoughtful response, Dennis. The obvious challenge here is not necessarily the manufacturers of anticholinergic OAB meds but the insurance carriers that mandate their use before considering beta agonists or third line therapies such ...